CA3159633A1 - Mrgprx2 antagonists and uses thereof - Google Patents

Mrgprx2 antagonists and uses thereof

Info

Publication number
CA3159633A1
CA3159633A1 CA3159633A CA3159633A CA3159633A1 CA 3159633 A1 CA3159633 A1 CA 3159633A1 CA 3159633 A CA3159633 A CA 3159633A CA 3159633 A CA3159633 A CA 3159633A CA 3159633 A1 CA3159633 A1 CA 3159633A1
Authority
CA
Canada
Prior art keywords
compound
alkyl
optionally substituted
skin
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3159633A
Other languages
English (en)
French (fr)
Inventor
Ferda CEVIKBAS
Christopher Pearson
Laura Gleave
Nina Connelly URSINYOVA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dermira Inc
Original Assignee
Dermira Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dermira Inc filed Critical Dermira Inc
Publication of CA3159633A1 publication Critical patent/CA3159633A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3159633A 2019-11-05 2020-11-05 Mrgprx2 antagonists and uses thereof Pending CA3159633A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962931186P 2019-11-05 2019-11-05
US62/931,186 2019-11-05
US201962931576P 2019-11-06 2019-11-06
US62/931,576 2019-11-06
US202063046481P 2020-06-30 2020-06-30
US63/046,481 2020-06-30
PCT/US2020/059228 WO2021092264A1 (en) 2019-11-05 2020-11-05 MrgprX2 ANTAGONISTS AND USES THEREOF

Publications (1)

Publication Number Publication Date
CA3159633A1 true CA3159633A1 (en) 2021-05-14

Family

ID=73740488

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3159633A Pending CA3159633A1 (en) 2019-11-05 2020-11-05 Mrgprx2 antagonists and uses thereof

Country Status (8)

Country Link
US (1) US20230002336A1 (https=)
EP (1) EP4055011A1 (https=)
JP (1) JP7787811B2 (https=)
CN (1) CN114728919B (https=)
AU (1) AU2020380926A1 (https=)
CA (1) CA3159633A1 (https=)
IL (1) IL292693A (https=)
WO (1) WO2021092264A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115850094B (zh) * 2022-09-07 2025-02-11 北华航天工业学院 一种利用1,2-环氧丁烷合成β-氨基醇的方法
WO2025002360A1 (zh) * 2023-06-30 2025-01-02 北京普祺医药科技股份有限公司 一种mrgprx2拮抗剂、药物组合物以及其用途
WO2025042736A1 (en) 2023-08-18 2025-02-27 Incyte Corporation Bicyclic heterocycles as mrgprx2 antagonists
WO2025160430A1 (en) 2024-01-25 2025-07-31 Incyte Corporation Bicyclic heterocycles as mrgprx2 antagonists
KR20250121245A (ko) * 2024-02-02 2025-08-12 삼진제약주식회사 MRGPRX2 (Mas-related G-protein coupled receptor member X2) 길항제로서 신규 화합물 및 이를 포함하는 약학적 조성물
WO2025222040A1 (en) 2024-04-19 2025-10-23 Escient Pharmaceuticals, Inc. Mrgprx2 modulators for use in treating mrgprx2 dependent conditions in subjects with low ige
TW202547469A (zh) 2024-04-19 2025-12-16 日商杏林製藥股份有限公司 Mrgprx2拮抗劑、包含mrgprx2拮抗劑之醫藥組成物及治療mrgprx2媒介疾病或病症之方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4152442A (en) * 1975-06-05 1979-05-01 Lilly Industries Limited Certain acylamino-oxa (or thia) diazoles in treatment of hypersensitivity conditions
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
DE3272640D1 (en) * 1982-01-22 1986-09-18 Basf Ag Thiadiazole derivatives, process for their preparation, and their use in combatting unwanted plant growth
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
JP2006522744A (ja) * 2003-04-11 2006-10-05 ノボ　ノルディスク　アクティーゼルスカブ グルココルチコイド受容体アゴニスト療法に伴う副作用を最小化するための、１１β−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤およびグルココルチコイド受容体アゴニストを使用する併用療法
GB0308511D0 (en) * 2003-04-14 2003-05-21 Astex Technology Ltd Pharmaceutical compounds
EP1658072A4 (en) * 2003-08-21 2009-03-25 Pfizer Prod Inc Compounds for the Treatment of Neurodegenerative Diseases
DE102004009933A1 (de) * 2004-02-26 2005-09-15 Merck Patent Gmbh Verwendung von Thiadiazolharnstoffderivaten
EP2125799A1 (en) * 2007-02-28 2009-12-02 Smithkline Beecham Corporation Thiadiazole derivatives, inhibitors of stearoyl-coa desaturase
WO2009086303A2 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
MX2010013705A (es) * 2008-06-13 2011-02-25 Bayer Cropscience Ag Nuevas amidas y tioamidas heteroaromaticas como plaguicidas.
WO2010073011A2 (en) * 2008-12-23 2010-07-01 Betagenon Ab Compounds useful as medicaments
US8377639B2 (en) * 2009-06-26 2013-02-19 University Of Massachusetts Compounds for modulating RNA binding proteins and uses therefor
PT2673285T (pt) * 2010-12-09 2017-10-19 Wockhardt Ltd Resumo
CA2850551A1 (en) * 2011-09-30 2013-04-04 Endo Pharmaceuticals Inc. Pyridine derivatives
ES2670517T3 (es) * 2013-01-30 2018-05-30 Sumitomo Chemical Company, Limited Compuesto de amida, un agente de control de plagas de artrópodos y un método para controlar las plagas de artrópodos
EP3444251B1 (en) * 2013-12-11 2023-06-07 Biogen MA Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
US10253023B2 (en) * 2014-10-06 2019-04-09 Merck Patent Gmbh Heteroaryl compounds as BTK inhibitors and uses thereof
CA3055194A1 (en) * 2017-03-02 2018-09-07 Assembly Biosciences, Inc. Cyclic sulfamide compounds and methods of using same

Also Published As

Publication number Publication date
JP2022554392A (ja) 2022-12-28
EP4055011A1 (en) 2022-09-14
IL292693A (en) 2022-07-01
JP7787811B2 (ja) 2025-12-19
US20230002336A1 (en) 2023-01-05
AU2020380926A1 (en) 2022-05-26
CN114728919A (zh) 2022-07-08
WO2021092264A1 (en) 2021-05-14
CN114728919B (zh) 2025-12-30

Similar Documents

Publication Publication Date Title
JP7712922B2 (ja) 炎症性障害を治療するためのＭｒｇｐｒＸ２アンタゴニスト
JP7827911B2 (ja) ＭｒｇｐｒＸ２アンタゴニストおよびその使用
CA3159633A1 (en) Mrgprx2 antagonists and uses thereof
CN102482249B (zh) 用于治疗皮肤病症或疾病状态的tofa类似物
EP2861580B1 (en) Seca inhibitors and methods of making and using thereof
CN112839942A (zh) 作为组蛋白去乙酰酶6抑制剂的1,3,4-噁二唑衍生物化合物以及包含其的药物组合物
CN101456872A (zh) 噻唑并[3,2-a]嘧啶类衍生物及其应用
EP4520752A1 (en) Carebastine salt and use thereof
CN111670189A (zh) 对rsv具有活性的环烷基取代的吡唑并嘧啶
CN120603813A (zh) 2-氨基-n-(4-氨基-3,4-二氧代-1-(2-氧代吡咯烷-3-基)丁-2-基)苯甲酰胺衍生物作为蛋白酶抑制剂用于治疗或预防冠状病毒感染
JP7813733B2 (ja) Ｉｒａｋ４阻害剤及びそれらの局所的使用方法
EA010293B1 (ru) Частицеобразующие композиции, содержащие конденсированные пирролокарбазолы
US20250353818A1 (en) Compounds
KR20260053507A (ko) 화합물
JPH0665205A (ja) 新規ジテルペンアルカロイド及びジテルペンアルカロイド類を有効成分とする心疾患治療薬
HK1206736B (en) Seca inhibitors and methods of making and using thereof
HK1189886B (en) Tofa analogs useful in treating dermatological disorders or conditions

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241030

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241030

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241030

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20241101

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20241101

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241210

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241218

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20241218

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20241218

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241218

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250424

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250429

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251022

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251022

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260218